Sentence: Although progression-free survival with the bevacizumab plus capecitabine combination is inferior to that noted with bevacizumab plus paclitaxel , we suggest that physicians should consider possible predictive risk factors for overall survival , individual 's treatment priorities , and the differing safety profiles .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['bevacizumab', 'capecitabine'], 'is_context_needed': True}, {'class': 'POS', 'spans': [2, 3], 'is_context_needed': False}]